|
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer
|
|
O25-227-1
|
|
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer
|
|
Dr. Omar Ibrahim
|
|
The purpose of this study is to see how effective the injection of the radiation enhancer called JNJ-90301900 into tumor(s), before receiving concurrent chemoradiotherapy (cCRT) followed by immunotherapy (cIT) is, compared to receiving cCRT alone followed by cIT (without JNJ-90301900).
|
Cancer - Lung
|
|
|
Check with study contact
|
|
Maria Keane. Telephone: 860-679-1144. Email: mkeane@uchc.edu
|
|
Enrolling/recruiting.
|
|
|